Latest Articles
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - The AI Journal
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer The AI Journal
Published: Dec. 22, 2025, 7:31 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - itemonline.com
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer itemonline.com
Published: Dec. 22, 2025, 7:30 a.m.
Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer - OncLive
Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer OncLive
Published: Dec. 22, 2025, 5:26 a.m.
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial - geneonline.com
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com
Published: Dec. 21, 2025, 12:34 p.m.
Fruquintinib and Sintilimab Treat Advanced Endometrial Cancer - Bioengineer.org
Fruquintinib and Sintilimab Treat Advanced Endometrial Cancer Bioengineer.org
Published: Dec. 21, 2025, 11:59 a.m.
Brian Slomovitz: New Study on PARP Therapy Advances in Endometrial Cancer - Oncodaily
Brian Slomovitz: New Study on PARP Therapy Advances in Endometrial Cancer Oncodaily
Published: Dec. 19, 2025, 7:56 p.m.
Correlation between Polycomb repressive complex proteins and epithelial-mesenchymal transition-associated genes in endometriotic tissues.
Endometriosis is a condition in which functional endometrial glands and stroma are found to grow outside the uterine cavity that can lead to symptoms like dysmenorrhea, dyspareunia, adhesions, and infertility. …
Published: Dec. 19, 2025, midnight
The Molecular Classification Ushers in a New Era for the Treatment of Advanced and Recurrent Endometrial Cancer - Frontiers
The Molecular Classification Ushers in a New Era for the Treatment of Advanced and Recurrent Endometrial Cancer Frontiers
Published: Dec. 18, 2025, 3:05 p.m.
Pharmacophoric Investigation of a Natural Product-like Class of Aromatase Inhibitors Using Molecular Modeling.
Endometriosis is a condition affecting approximately 10% of reproductive-age women in which endometrial tissue is found in locations outside the uterus, often causing debilitating symptoms. Aromatase, an enzyme that also …
Published: Dec. 18, 2025, midnight
Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions - Frontiers
Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions Frontiers
Published: Dec. 17, 2025, 5:24 p.m.
Link copied to clipboard!